Ekaterina Nevedomskaya YOU? Author Swipe

Last 10y

Dual targeting of the androgen receptor and <span>PI3K</span> / <span>AKT</span> / <span>mTOR</span> pathways in prostate cancer models improves antitumor efficacy and promotes cell apoptosis Open

Tatsuo Sugawara, Ekaterina Nevedomskaya, Simon Heller, Annika Böhme, Ralf Lesche , et al. · 2024

Prostate cancer is a frequent malignancy in older men and has a very high 5‐year survival rate if diagnosed early. The prognosis is much less promising if the tumor has already spread outside the prostate gland. Targeted treatments mainly …

Preclinical Anticipation of On- and Off-Target Resistance Mechanisms to Anti-Cancer Drugs: A Systematic Review Open

Paulina J. Dziubańska-Kusibab, Ekaterina Nevedomskaya, Bernard Haendler · 2024

The advent of targeted therapies has led to tremendous improvements in treatment options and their outcomes in the field of oncology. Yet, many cancers outsmart precision drugs by developing on-target or off-target resistance mechanisms. G…

Survivorship Data in Prostate Cancer: Where Are We and Where Do We Need To Be? Open

Beth Russell, Katharina Beyer, Ailbhe Lawlor, Monique J. Roobol, Lionne D. F. Venderbos , et al. · 2023

Grade Group 1 Prostate Cancers Exhibit Tumor-defining Androgen Receptor–driven Programs Open

Simon Linder, Tesa Severson, Koen J.C. van der Mijn, Ekaterina Nevedomskaya, Joseph C. Siefert , et al. · 2023

Grade group 1 (GG1) primary prostate cancers with a pathologic Gleason score of 6 are considered indolent and generally not associated with fatal outcomes, so treatment is not indicated for most cases. These low-grade cancers have an overa…

Targeting fatty acid oxidation via Acyl-CoA binding protein hinders glioblastoma invasion Open

Ceren Duman, Barbara Di Marco, Ekaterina Nevedomskaya, Berk Ulug, Ralf Lesche , et al. · 2023

Table S5 from Mastermind-Like 3 Controls Proliferation and Differentiation in Neuroblastoma Open

Guus J.J.E. Heynen, Ekaterina Nevedomskaya, Sander Palit, Noorjahan Jagalur Basheer, Cor Lieftink , et al. · 2023

Supplementary Table 5: Sources of publicly available ChIP-seq data for p300 and H3K27me1 in SK-N-SH

Supplemental doc from Mastermind-Like 3 Controls Proliferation and Differentiation in Neuroblastoma Open

Guus J.J.E. Heynen, Ekaterina Nevedomskaya, Sander Palit, Noorjahan Jagalur Basheer, Cor Lieftink , et al. · 2023

Supplementary method, Supplementary figures and supplementary figure legends: Supplementary Figure 1. Viral VBIM integration site in MAML3 gene and equal sensitivity to cisplatin of parental and SD3.23 cells. Supplementary Figure 2. Overex…

Supplemental doc from Mastermind-Like 3 Controls Proliferation and Differentiation in Neuroblastoma Open

Guus J.J.E. Heynen, Ekaterina Nevedomskaya, Sander Palit, Noorjahan Jagalur Basheer, Cor Lieftink , et al. · 2023

Supplementary method, Supplementary figures and supplementary figure legends: Supplementary Figure 1. Viral VBIM integration site in MAML3 gene and equal sensitivity to cisplatin of parental and SD3.23 cells. Supplementary Figure 2. Overex…

Table S4 from Mastermind-Like 3 Controls Proliferation and Differentiation in Neuroblastoma Open

Guus J.J.E. Heynen, Ekaterina Nevedomskaya, Sander Palit, Noorjahan Jagalur Basheer, Cor Lieftink , et al. · 2023

Supplementary Table 4: Read counts, number of mapped reads and number of peaks for the RARα and MAML3 ChI

Table S6 from Mastermind-Like 3 Controls Proliferation and Differentiation in Neuroblastoma Open

Guus J.J.E. Heynen, Ekaterina Nevedomskaya, Sander Palit, Noorjahan Jagalur Basheer, Cor Lieftink , et al. · 2023

Supplementary Table 6: RNA sequencing read depths for SK-N-SH and SD3.23 cells.

Table S3 from Mastermind-Like 3 Controls Proliferation and Differentiation in Neuroblastoma Open

Guus J.J.E. Heynen, Ekaterina Nevedomskaya, Sander Palit, Noorjahan Jagalur Basheer, Cor Lieftink , et al. · 2023

Supplementary Table 3: List of RA target genes that show loss of activation upon RA treatment in MAML

Table S6 from Mastermind-Like 3 Controls Proliferation and Differentiation in Neuroblastoma Open

Guus J.J.E. Heynen, Ekaterina Nevedomskaya, Sander Palit, Noorjahan Jagalur Basheer, Cor Lieftink , et al. · 2023

Supplementary Table 6: RNA sequencing read depths for SK-N-SH and SD3.23 cells.

Table S2 from Mastermind-Like 3 Controls Proliferation and Differentiation in Neuroblastoma Open

Guus J.J.E. Heynen, Ekaterina Nevedomskaya, Sander Palit, Noorjahan Jagalur Basheer, Cor Lieftink , et al. · 2023

Supplementary Table 2: List of genes defined as RA target genes on basis of RARα binding within 20 kb of the Gene Symbol

Table S1 from Mastermind-Like 3 Controls Proliferation and Differentiation in Neuroblastoma Open

Guus J.J.E. Heynen, Ekaterina Nevedomskaya, Sander Palit, Noorjahan Jagalur Basheer, Cor Lieftink , et al. · 2023

Supplementary Table 1: List of genes that have a fold change in expression of at least log2FC > 1.5 and adjust

Table S4 from Mastermind-Like 3 Controls Proliferation and Differentiation in Neuroblastoma Open

Guus J.J.E. Heynen, Ekaterina Nevedomskaya, Sander Palit, Noorjahan Jagalur Basheer, Cor Lieftink , et al. · 2023

Supplementary Table 4: Read counts, number of mapped reads and number of peaks for the RARα and MAML3 ChI

Table S5 from Mastermind-Like 3 Controls Proliferation and Differentiation in Neuroblastoma Open

Guus J.J.E. Heynen, Ekaterina Nevedomskaya, Sander Palit, Noorjahan Jagalur Basheer, Cor Lieftink , et al. · 2023

Supplementary Table 5: Sources of publicly available ChIP-seq data for p300 and H3K27me1 in SK-N-SH

Table S2 from Mastermind-Like 3 Controls Proliferation and Differentiation in Neuroblastoma Open

Guus J.J.E. Heynen, Ekaterina Nevedomskaya, Sander Palit, Noorjahan Jagalur Basheer, Cor Lieftink , et al. · 2023

Supplementary Table 2: List of genes defined as RA target genes on basis of RARα binding within 20 kb of the Gene Symbol

Data from Mastermind-Like 3 Controls Proliferation and Differentiation in Neuroblastoma Open

Guus J.J.E. Heynen, Ekaterina Nevedomskaya, Sander Palit, Noorjahan Jagalur Basheer, Cor Lieftink , et al. · 2023

Neuroblastoma cell lines can differentiate upon treatment with retinoic acid (RA), a finding that provided the basis for the clinical use of RA to treat neuroblastoma. However, resistance to RA is often observed, which limits its clinical …

Table S3 from Mastermind-Like 3 Controls Proliferation and Differentiation in Neuroblastoma Open

Guus J.J.E. Heynen, Ekaterina Nevedomskaya, Sander Palit, Noorjahan Jagalur Basheer, Cor Lieftink , et al. · 2023

Supplementary Table 3: List of RA target genes that show loss of activation upon RA treatment in MAML

Table S1 from Mastermind-Like 3 Controls Proliferation and Differentiation in Neuroblastoma Open

Guus J.J.E. Heynen, Ekaterina Nevedomskaya, Sander Palit, Noorjahan Jagalur Basheer, Cor Lieftink , et al. · 2023

Supplementary Table 1: List of genes that have a fold change in expression of at least log2FC > 1.5 and adjust

Data from Mastermind-Like 3 Controls Proliferation and Differentiation in Neuroblastoma Open

Guus J.J.E. Heynen, Ekaterina Nevedomskaya, Sander Palit, Noorjahan Jagalur Basheer, Cor Lieftink , et al. · 2023

Neuroblastoma cell lines can differentiate upon treatment with retinoic acid (RA), a finding that provided the basis for the clinical use of RA to treat neuroblastoma. However, resistance to RA is often observed, which limits its clinical …

Table S6 from SRC3 Phosphorylation at Serine 543 Is a Positive Independent Prognostic Factor in ER-Positive Breast Cancer Open

Wilbert Zwart, Koen D. Flach, Bharath Rudraraju, Tarek M.A. Abdel-Fatah, Ondřej Gojiš , et al. · 2023

Motif analyses for chromatin binding sites shared or selectively enriched for SRC3-pS543 and ERï�¡ in tumor #1.

Supplemtary Figures S 1-14 from SRC3 Phosphorylation at Serine 543 Is a Positive Independent Prognostic Factor in ER-Positive Breast Cancer Open

Wilbert Zwart, Koen D. Flach, Bharath Rudraraju, Tarek M.A. Abdel-Fatah, Ondřej Gojiš , et al. · 2023

S1: Image of full size blot for figure 1A; S2: Image of full size blot for figure 1B; S3: SRC3-pS543 and SRC3 chromatin binding patterns in MCF7 cells; S4: Venn diagram of SRC1, SRC2 and SRC3-pS543 enriched binding sites; S5: A. ChIP-QPCR …

Table S5 from SRC3 Phosphorylation at Serine 543 Is a Positive Independent Prognostic Factor in ER-Positive Breast Cancer Open

Wilbert Zwart, Koen D. Flach, Bharath Rudraraju, Tarek M.A. Abdel-Fatah, Ondřej Gojiš , et al. · 2023

GO pathway analysis of genes with a transcription start site

Table S7: from SRC3 Phosphorylation at Serine 543 Is a Positive Independent Prognostic Factor in ER-Positive Breast Cancer Open

Wilbert Zwart, Koen D. Flach, Bharath Rudraraju, Tarek M. Abdel-Fatah, Ondřej Gojiš , et al. · 2023

Tumour biomarkers and correlation with SRC3 and SRC3-pS543

Supplemtary Figures S 1-14 from SRC3 Phosphorylation at Serine 543 Is a Positive Independent Prognostic Factor in ER-Positive Breast Cancer Open

Wilbert Zwart, Koen D. Flach, Bharath Rudraraju, Tarek M.A. Abdel-Fatah, Ondřej Gojiš , et al. · 2023

S1: Image of full size blot for figure 1A; S2: Image of full size blot for figure 1B; S3: SRC3-pS543 and SRC3 chromatin binding patterns in MCF7 cells; S4: Venn diagram of SRC1, SRC2 and SRC3-pS543 enriched binding sites; S5: A. ChIP-QPCR …

Table S5 from SRC3 Phosphorylation at Serine 543 Is a Positive Independent Prognostic Factor in ER-Positive Breast Cancer Open

Wilbert Zwart, Koen D. Flach, Bharath Rudraraju, Tarek M. Abdel-Fatah, Ondřej Gojiš , et al. · 2023

GO pathway analysis of genes with a transcription start site

Table S7: from SRC3 Phosphorylation at Serine 543 Is a Positive Independent Prognostic Factor in ER-Positive Breast Cancer Open

Wilbert Zwart, Koen D. Flach, Bharath Rudraraju, Tarek M.A. Abdel-Fatah, Ondřej Gojiš , et al. · 2023

Tumour biomarkers and correlation with SRC3 and SRC3-pS543

Table S1 from SRC3 Phosphorylation at Serine 543 Is a Positive Independent Prognostic Factor in ER-Positive Breast Cancer Open

Wilbert Zwart, Koen D. Flach, Bharath Rudraraju, Tarek M. Abdel-Fatah, Ondřej Gojiš , et al. · 2023

QPCR primer sequences for ChIP validations.

Table S1 from SRC3 Phosphorylation at Serine 543 Is a Positive Independent Prognostic Factor in ER-Positive Breast Cancer Open

Wilbert Zwart, Koen D. Flach, Bharath Rudraraju, Tarek M.A. Abdel-Fatah, Ondřej Gojiš , et al. · 2023

QPCR primer sequences for ChIP validations.

Fetching topic information...